<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.ontology.v1.OntologyDrugSummaryOutput xmlns:ns2="local" id="93164" name="lumasiran"><HDS>Phase 3 Clinical</HDS><RegulatoryDesignations><RegulatoryDesignation id="3">Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><RegulatoryDesignation id="10">PRIME</RegulatoryDesignation></RegulatoryDesignations><Actions><Action id="90388" type="primary">Hydroxyacid oxidase 1 modulator</Action><Action id="26035" type="secondary">siRNA agent</Action></Actions><Indications><Indication id="1822" type="primary">Hyperoxaluria</Indication></Indications><Entities><Entity>Biological</Entity></Entities><OriginatorCompany id="29927">Alnylam Pharmaceuticals Inc</OriginatorCompany></ns2:com.thomsonreuters.ls.service.contract.soap.ontology.v1.OntologyDrugSummaryOutput>